Last reviewed · How we verify
NCT03540407
Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.
Phase 2 trial testing Oncoxin-Viusid® in Cervical Carcinoma Stage II in 66 participants. Completed in 30 September 2019.
1 February 2019
Quick facts
| Lead sponsor | Catalysis SL |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 66 |
| Start date | 7 January 2015 |
| Primary completion | 1 February 2019 |
| Estimated completion | 30 September 2019 |
| Sites | 1 location across Cuba |
Drugs / interventions tested
- Oncoxin-Viusid®
- Placebo
Conditions studied
- Cervical Carcinoma Stage II — all drugs for Cervical Carcinoma Stage II →
- Cervical Carcinoma Stage III — all drugs for Cervical Carcinoma Stage III →
- Cervical Carcinoma Stage IV — all drugs for Cervical Carcinoma Stage IV →
- Endometrial Adenocarcinoma Stage II — all drugs for Endometrial Adenocarcinoma Stage II →
Sponsor
Catalysis SL — full company profile →
Who can join
Adults 18 to 80, female only, with Cervical Carcinoma Stage II or Cervical Carcinoma Stage III. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy of oral solution Oncoxin-Viusid in the reduction of acute toxicity of Radiotherapy (RTP) and Chemotherapy (QTP) in patients with histological diagnosis of cervical cancer and endometrial adenocarcinoma. This is a phase II, prospective, randomized and double blind clinical trial, which will include 66 patients assigned to 2 treatment arms: 33 patients will receive conventional treatment, plus a placebo of the nutritional supplement and another 33 patients will receive along with the conventional treatment the Oncoxin-Viusid nutritional supplement produced by the Catalysis Laboratories of Spain. Patients will receive oral treatment throughout the onco-specific treatment and up to 3 weeks after completion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03540407
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oncoxin-Viusid®
Trials testing the same drug.
- NCT03541772 — Evaluation of Oncoxin-Viusid® in Head and Neck Cancer · Phase 2 · completed
Other recruiting trials for Cervical Carcinoma Stage II
Currently open trials in the same condition.
- NCT07343531 — A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brach · NA · recruiting
Other Catalysis SL trials
Trials by the same sponsor.
- NCT07179237 — Efficacy of Carminal in Helicobacter Pylori Gastritis · Phase 2 · recruiting
- NCT06363201 — Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumour · NA · not yet recruiting
- NCT05916911 — Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In P · Phase 4 · unknown
- NCT06496087 — Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment · NA · completed
- NCT06361992 — Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03540407 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Catalysis SL
- Last refreshed: 23 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03540407.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing